How ValueAct Shook Off Its Big Loss from Valeant
The hedge fund firm, headed by Jeff Ubben, did not suffer the same fate as other major shareholders of the ailing pharmaceutical concern.
Stephen Taub
January 6, 2017
Valeant Pharmaceuticals International Inc. headquarters stands in Bridgewater Township, New Jersey, U.S., on Thursday, Aug. 4, 2016. Valeant Pharmaceuticals International Inc. is scheduled to release earnings figures on Aug. 9. Photographer: Ron Antonelli/Bloomberg
Ron Antonelli/Bloomberg
